IFNA1 and chronic hepatitis B virus infection: Although IFN-α and its pegylated form (Peg-IFN-α) have been used as a first line therapy of chronic hepatitis B for more than 20 years, the sustained response rate to IFN treatment remains far from satisfying [26–28].